Phacilitate Leaders Forum

17th - 18th SEPTEMBER 2019



Andreas  Schmiede

Andreas Schmiede

Head of CDMO Business Unit, apceth Biopharma

Since September 2017  Head of CDMO Business at apceth Biopharma in Ottobrunn (Munich) and part of the Senior Management Team. Apceth Biopharma GmbH is a leading European Development and Manufacturing Organization for complex cell and gene therapy products and is recognized as one of Europe’s pioneers in the field of cell-based gene therapies.

2014 – 2017 Senior leadership functions at Baxter Baxalta / Shire for Hematology, Immunology and rare disease markets working within Operations Strategy Group in TechOps and Intercontinental division of Baxalta. Developing manufacturing access strategies (single use technologies) for intercontinental region and emerging markets to drive Baxalta´s growth strategy initiative. Managing complex multi-million USD Tech Transfer Programs.  

2010- 2014 Cofounder of  Brasil Bioscience in Brasil and consultant for the Ministry of health for the development of point of care devices for tropical and infectious  diseases. Regulatory Strategy Consultant in Brazil for small and midsize European Pharma companies.  

1996 – 2009 Several Senior leadership position at QIAGEN GmbH, a provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. Responsible for plastic development and general Engineering, worldwide Product Implementation and New Technologies as well as M&A and Due diligence. Member of the Portfolio Team Application DNA and the Global Operation leadership Team. Co-inventor of a leading QIAGEN, QIAcube automation platform.

Biochemist by formation, Phd (Dr rer nat) form the Heinrich Heine University of Düsseldorf in the field of protein chemistry and molecular biology.

  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Jean-Philippe Combal
    GenSight Biologics
  • The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.
    Michael Covington
    Juno Therapeutics, Inc
  • It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance
    Bertrand Alexandre
  • Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.
    Dr Ohad Karnieli
    Karnieli Ltd